ストックスクリーナーアプリを入手
18.31
0.54%
-0.10
前日終値:
$18.41
開ける：
$19.07
24時間の取引高:
2.51M
Relative Volume:
2.42
時価総額：
$1.55B
収益：
$42.95M
当期純損益:
$-130.01M
株価収益率:
-11.25
EPS:
-1.6278
ネットキャッシュフロー:
$-19.66M
1週間 パフォーマンス:
+7.08%
1か月 パフォーマンス:
+1.67%
6か月 パフォーマンス:
+15.67%
1年 パフォーマンス:
+307.80%
1日の値動き範囲:
$17.91
$19.31
1週間の範囲:
$17.21
$19.31
52週間の値動き範囲:
$4.12
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
名前
Monte Rosa Therapeutics Inc
セクター
電話
617-949-2643
住所
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
18.31 | 1.55B | 42.95M | -130.01M | -19.66M | -1.6278 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | 開始されました | Wedbush | Outperform |
| 2023-01-03 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | 開始されました | UBS | Buy |
| 2022-08-15 | 開始されました | Jefferies | Buy |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2022-02-10 | 開始されました | Wells Fargo | Equal Weight |
| 2021-10-14 | 開始されました | SVB Leerink | Mkt Perform |
すべてを表示
Monte Rosa Therapeutics Inc (GLUE) 最新ニュース
COO of Monte Rosa (NASDAQ: GLUE) sells 2,176 shares under 10b5-1 plan - Stock Titan
Monte Rosa (NASDAQ: GLUE) CSO sells 3,000 shares under 10b5-1 plan - Stock Titan
Monte Rosa Therapeutics Inc (GLUE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Monte Rosa Therapeutics Inc (GLUE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Monte Rosa Therapeutics Inc (GLUE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Monte Rosa Therapeutics Inc (GLUE) Valuation: PE, PB & Fair Value Analysis - TradingKey
BVF Inc. IL Decreases Stock Holdings in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics Inc - TradingKey
Monte Rosa Therapeutics Inc (GLUE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GLUE (NASDAQ: GLUE) option exercise yields 2,176 shares planned for sale on 06/17/2026 - Stock Titan
Monte Rosa Therapeutics Inc (GLUE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO) - The Globe and Mail
Kymera, Monte Rosa among gainers as Novartis inks deal for molecular glue drugs - MSN
Monte Rosa Therapeutics, Inc. $GLUE Shares Sold by Alphabet Inc. - MarketBeat
Director at Monte Rosa (GLUE) awarded 25,800 stock options - Stock Titan
Monte Rosa Therapeutics (GLUE) director receives 25,800 stock options grant - Stock Titan
Monte Rosa Therapeutics (GLUE) director gets 25,800 options grant - Stock Titan
Monte Rosa Therapeutics (GLUE) grants director Jan Skvarka 25,800 options - Stock Titan
Monte Rosa Therapeutics (GLUE) director awarded 25,800 stock options - Stock Titan
Monte Rosa Therapeutics (GLUE) director granted 25,800 stock options - Stock Titan
Director at Monte Rosa (NASDAQ: GLUE) awarded 25,800 stock options - Stock Titan
Monte Rosa: Initiating Coverage With A Buy On Degrader Platform Potential - Seeking Alpha
Monte Rosa Therapeutics (GLUE) reports Q1 loss, misses revenue estimates - MSN
Monte Rosa Therapeutics (NASDAQ: GLUE) shareholders elect directors, ratify auditor - Stock Titan
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Cartesian Therapeutics (RNAC) and Abbott Laboratories (ABT) - The Globe and Mail
GLUE earnings ahead: Can Monte Rosa rebound from revenue miss? - Investing.com
GLUE Technical Analysis & Stock Price Forecast - Intellectia AI
GLUE Technical Analysis | Trend, Signals & Chart Patterns | MONTE ROSA THERAPEUTICS INC (NASDAQ:GLUE) - ChartMill
Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy - Insider Monkey
We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate - Moomoo
10 Best Growth Stocks Under $20 to Buy - Insider Monkey
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Monte Rosa (NASDAQ: GLUE) CEO sells 5,466 shares under Rule 10b5-1 plan - Stock Titan
Monte Rosa Therapeutics (GLUE) amends Form 144; RSU award and sales noted - Stock Titan
Monte Rosa (GLUE) insider Markus Warmuth reports multiple sales on Form 144 - Stock Titan
Monte Rosa Therapeutics (GLUE) CSO sells 6,000 shares under 10b5-1 plan - Stock Titan
[144] Monte Rosa Therapeutics, Inc. SEC Filing - Stock Titan
Monte Rosa COO Jennifer Champoux sells $43,500 in stock By Investing.com - Investing.com Nigeria
Monte Rosa COO Jennifer Champoux sells $43,500 in stock - Investing.com India
Monte Rosa Therapeutics (NASDAQ: GLUE) COO exercises options and sells 2,175 shares - Stock Titan
GLUE (NASDAQ: GLUE) Form 144: proposed sale of 2,175 shares - Stock Titan
Monte Rosa (NASDAQ: GLUE) COO exercises options and sells 2,176 shares under plan - Stock Titan
Monte Rosa Therapeutics director sells $180,100 of Glue shares By Investing.com - Investing.com India
Monte Rosa Therapeutics director sells $180,100 of Glue shares - Investing.com UK
Monte Rosa Therapeutics (GLUE) director exercises options and sells 10K shares - Stock Titan
Monte Rosa Therapeutics Inc. (GLUE) Q1 2026 Earnings: Wider-than-Expected Loss Compounds Investor CautionRevenue Per Share - lwvtexas.org
IDEA Pharma recognizes Monte Rosa Therapeutics for advancing MGD drug development - Traders Union
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Vanguard Group Inc. Has $50.91 Million Position in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Monte Rosa Therapeutics Inc (GLUE) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):